PI 0824

Drug Profile

PI 0824

Alternative Names: Peptide immunotherapy - Peptimmune; PI-0824

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator Peptimmune
  • Class Peptides; Skin disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris

Highest Development Phases

  • No development reported Pemphigus vulgaris

Most Recent Events

  • 13 Dec 2007 Orphan Europe has been acquired by Recordati
  • 15 Nov 2006 Peptimmune and Orphan Europe have entered into an agreement to co-promote and co-develop PI 0824 for Pemphigus vulgaris
  • 31 May 2005 Peptimmune has completed a phase trial in Pemphigus vulgaris in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top